TONSL-AS1: A Potential Drug Target and Biomarker (G100287098)

Target Name: TONSL-AS1

NCBI ID: G100287098

TONSL-AS1

Other Name(s): TONSL antisense RNA 1

TONSL-AS1: A Potential Drug Target and Biomarker

Tumor suppressor genes (TSGs) are essential for maintaining tissue homeostasis and have been implicated in various diseases, including cancer. Oncogenes, on the other hand, promote tumor growth and have also been implicated in various diseases. The balance between TSGs and oncogenes is crucial for maintaining tissue health and preventing diseases. One of the key factors in this balance is the tumor suppressor gene (TSG) TONSL-AS1.

TSG TONSL-AS1 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker in various diseases. It is a key regulator of the cell cycle, and its levels have been shown to be reduced in various types of cancer. TONSL-AS1 has also been shown to play a role in cell signaling pathways, including the regulation of cell adhesion, angiogenesis, and cancer progression.

One of the key functions of TONSL-AS1 is its role in regulating the cell cycle. The cell cycle is the process by which cells grow, divide, and replicate their genetic material. TONSL-AS1 is a key regulator of the cell cycle, and its levels have been shown to be reduced in various types of cancer. This suggests that TONSL-AS1 may be a useful drug target for cancer treatment.

In addition to its role in cell cycling, TONSL-AS1 has also been shown to play a role in cell signaling pathways. It has been shown to regulate several signaling pathways, including the regulation of cell adhesion, angiogenesis, and cancer progression. TONSL-AS1 has also been shown to play a role in the regulation of theNotch signaling pathway, a pathway that is involved in the regulation of cell proliferation and survival.

TSG TONSL-AS1 has also been shown to have potential as a biomarker in various diseases. The levels of TONSL-AS1 have been shown to be reduced in various types of cancer, including breast, ovarian, and colorectal cancers. This suggests that TONSL-AS1 may be a useful biomarker for cancer diagnosis and treatment.

In conclusion, TONSL-AS1 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker in various diseases. Its role in regulating the cell cycle and cell signaling pathways makes it a promising target for cancer treatment. Further research is needed to fully understand the role of TONSL-AS1 in diseases and to develop effective treatments.

Protein Name: TONSL Antisense RNA 1

The "TONSL-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TONSL-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets